XSHE
002437
Market cap1.18bUSD
Oct 09, Last price
3.69CNY
1D
4.53%
1Q
17.89%
Jan 2017
-54.79%
IPO
28.61%
Name
HARBIN GLORIA PHARMACEUTICALS Co Ltd
Chart & performance
P/E
21.83
P/S
3.85
EPS
0.17
Div yield, %
—
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
-7.45%
Revenues
2.14b
-12.51%
Net income
377m
+61.93%
CFO
273m
-33.48%
Dividend
Jun 28, 20190.012 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Harbin Gloria Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical enterprise primarily focused on the research, development, manufacturing, and commercialization of various medicinal products within the People's Republic of China. The company's comprehensive portfolio addresses a broad spectrum of therapeutic areas, including cardiac and cerebrovascular health, skeletal muscle system support, and urinary tract conditions. It also provides vitamins and minerals, as well as medications for oncology, endocrine disorders, anti-infective treatments, respiratory ailments, antihistamine purposes, and peptic concerns, among other pharmaceutical goods. Established in 2000, the firm's headquarters are located in Harbin, also situated in the People's Republic of China.
Key people
Runbao Li
Deputy General Manager · since 2023
Xiaohang Wang
Deputy General Manager · since 2023
Yueyin Liu
Deputy General Manager, Secretary of the Board, Director · since 2025
Leifeng Guo
Finance Director, General Manager, Director · since 2024
Jin Hu
Director · since 2025
Zhenyu Shen
Chairman of the Board · since 2025
Yubing Song
Staff Elected Director · since 2026
Kang Zhou
Deputy General Manager, Director · since 2022
Yi Chen
Independent Director · since 2025
Lida Wang
Independent Director · since 2025
Yuhong Xu
Independent Director · since 2026
Headquarters & legal address
滨市黑龙江省哈尔滨市呼兰区利民经济技术开发区北京路29号.
哈尔滨市, HL 100000
CN
哈尔滨市, HL 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||